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Abstract  16 
Background: Observational studies have suggested that perinatal outcomes are worse in offspring of 17 
cancer survivors. We conducted a systematic review and meta-analysis to examine the risks of perinatal 18 
complications in female cancer survivors diagnosed before the age of 40 years.  19 
Methods: All published articles on pregnancy, perinatal or congenital risks in female cancer survivors 20 
were screened for eligibility. PRISMA guidelines were followed.  21 
Results: Twenty-two studies met the inclusion criteria. Meta-analysis indicates that offspring of cancer 22 
survivors are at increased risk of prematurity (RR: 1.56; 95% CI 1.37 – 1.77)) and low birth weight (RR 23 
1.47; 95% CI 1.24 – 1.73) but not of being small for gestational age (RR 0.99; (95% CI 0.81 – 1.22). Cancer 24 
survivors have higher rates of elective (RR: 1.40; 95% CI 1.31 – 1.49) and emergency caesarean section 25 
(RR: 1.22; 95% CI 1.15 – 1.30) as well as assisted vaginal delivery (RR: 1.10; 95% CI 1.02 – 1.18) and are at 26 
increased risk of postpartum haemorrhage (RR: 1.18; 95% CI 1.02 – 1.36). The risk of congenital 27 
abnormalities also appears increased (RR 1.10; 95% CI 1.02 – 1.20) but this is likely to be an artefact of 28 
analysis. Although meta-analysis of the effects of radiotherapy was not possible for all outcomes, there 29 
was an increased risk of prematurity (RR 2.27; 95% CI 1.34 – 3.82) and consistent findings of low birth 30 
weight (RR 1.38-2.31). Risk of small for gestational age was increased only after high uterine 31 
radiotherapy dosage. 32 
Conclusion: The increased perinatal risks warrant a proactive approach from health care providers in 33 
both counselling and management of perinatal care for cancer survivors.  34 
Key words: cancer survivors; perinatal risk; premature delivery; postpartum haemorrhage; low birth 35 
weight; congenital abnormalities  36 
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Introduction 37 
Around 5% of all cancers are diagnosed before the age of 40 [1], and survival rates after cancer in 38 
children and young adults are relatively high with approximately 80% being alive five years after the 39 
diagnosis [2]. Building a family may be part of their future, and as societal changes have led women to 40 
delay childbirth, an increasing number of survivors have not started a family at the time of diagnosis. 41 
Future fertility prospects may be affected by  the administered cancer treatment, and pregnancy 42 
chances are about a third lower in cancer survivors as compared to the general population [3]. 43 
Nevertheless, many female survivors have the wish and the potential to become pregnant [4-7].  44 
Several studies have evaluated complications during pregnancy and labor in female cancer 45 
survivors in comparison to siblings or the general population. Increased risks for preterm birth were 46 
reported in the US Childhood Cancer Survivors Study (CCSS) and the British Childhood Cancer Survivors 47 
Study (BCCSS) [8, 9], as well as in other large populations with survivors diagnosed in their reproductive 48 
life [10, 11]. However, contrasting findings were observed for the risk of offspring being small for 49 
gestational age [8, 11, 12]. Despite being an important landmark in pregnancy planning for psychological 50 
reasons, less is known about the method of delivery in cancer survivors. Nonetheless, the largest studies 51 
showed decreased rates of spontaneous vaginal delivery and increased rates of caesarean section [9, 12-52 
14]. Some early studies suggested an increased relative risk of congenital abnormalities in the offspring 53 
of cancer survivors [15, 16]. These findings have not been confirmed in more recent analyses [9, 12, 17, 54 
18]. Due to the low prevalence of both cancer in children and young adults and of some pregnancy and 55 
labor complications, evaluation of these data benefits from large number of subjects being involved, 56 
giving increased statistical power. To synthesize the available data across studies, we performed a 57 
systematic review and meta-analysis.  58 
 59 
 60 
4 
 
Methods 61 
This review and meta-analysis was registered in PROSPERO (CRD42017078007) and the Preferred 62 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) were followed [19].  63 
The databases Embase, MEDLINE (via OvidSP), Web of Science, Cochrane and Google Scholar 64 
were used for the systematic search. Details of the full search strategy for each database are included in 65 
Appendix A (online only). Briefly, we searched for articles reporting on any perinatal outcomes 66 
(maternal and fetal/neonatal) in survivors of any cancer until the age of 40. The search was limited to 67 
the following criteria: reported between 1990 – September 2018; published in English. All titles and 68 
abstracts were reviewed to select potentially eligible studies by two independent reviewers (ALFvdK and 69 
TWK). Full text papers were retrieved to assess fulfillment of the selection criteria. Studies reporting on 70 
pregnancies and/or births of less than 50 cancer survivors and cohort studies that did not include a 71 
control group were excluded, as well as opinion papers or reviews. Cross-reference check of the 72 
retrieved studies was performed to identify additional studies that were overlooked during the initial 73 
search.  74 
The critical appraisal skills programme (CASP,https://casp-uk.net/) provides tools for a 75 
structured approach to finding evidence and appraising the evidence based on methodology and 76 
validity. The standardized checklist for cohort studies consists of eleven questions within three parts: 77 
“Are the results of the study valid” (Section A, focusing on bias and confounding), “What are the results” 78 
(Section B, on strength and precision), and “Will the results help locally” (Section C, on generalizability). . 79 
This assessment was performed by three independent authors (ALFvdK, TWK, RAA) and disagreements 80 
were discussed and resolved among them.  81 
Outcome measures that were included were: low birth weight (<2500g), preterm birth (<37 82 
weeks gestation), small for gestational age (<10th percentile), spontaneous vaginal delivery, assisted 83 
vaginal delivery, elective caesarean section, emergency caesarean section, antepartum haemorrhage (as 84 
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defined by the authors of included studies, including placenta praevia, placental abruption and other 85 
bleeding), postpartum haemorrhage, and congenital abnormalities.     86 
For all outcomes, incidence or prevalence numbers were extracted for both the cancer survivor 87 
group and the control group.  In addition, incidence or prevalence numbers from survivors treated with 88 
abdominal radiotherapy were extracted, or ‘any radiotherapy’ if no more details were available.  89 
Heterogeneity between the eligible studies was assessed using the I2 statistic, with I2 > 80% indicating 90 
high variation between included studies, I2 between 50% and 80% indicating moderate variation, and I2 91 
<50% indicating sufficient similarity between the studies to ensure that pooling was valid. When 92 
heterogeneity was considerable (i.e., I2 ≥50% and p<0.05), pooled estimates based on the random 93 
effects model were presented. Otherwise, pooled fixed effects were presented. Meta-analysis was only 94 
performed if more than two studies were available for the meta-analysis. Funnel plots were created to 95 
evaluate the possibility of publication bias. This type of graph are useful tools in meta-analyses and plots 96 
each study’s study precision on the y-axis and study result on the x-axis. In this way, studies with high 97 
precision are plotted near the average and studies with lower precision are spread evenly on its side in a 98 
funnel-shaped manner. Asymmetry of the resulting scatterplot can be a result of publication bias or 99 
other study heterogeneity and warrants further investigation of its cause. Summary measures of 100 
Relative Risk (RR) and 95% confidence intervals (95% CI) were obtained using standard meta-analysis in 101 
the R package meta [20, 21].   102 
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Results 103 
After exclusion of duplicates, the search yielded 2,922 citations. After screening of titles, 239 remained 104 
of which 192 could be excluded based on abstract or full-text, while 3 other publications were identified 105 
from cross-reference checking. The remaining 50 studies were included for CASP scoring, in which ≥9 106 
out of 11 points were required for inclusion in the meta-analysis. Studies reporting on cohorts from the 107 
same region were examined for overlapping data, and in these cases the oldest reports were excluded. 108 
A total of 22 studies were included for the meta-analysis [6, 8-14, 18, 22-34]. The list of included and 109 
excluded studies and their assigned CASP scores can be found in Appendix B (online only). 110 
 All 22 included studies were retrospective cohort studies. Most studies (n=15), especially the 111 
most recently reported, had obtained data by population registry linkage. One study was based on 112 
medical records [24], and six studies were based on questionnaire data [6, 22, 27, 31-33].  113 
 While all studies included survivors of cancer, age at diagnosis varied. Eight studies had included 114 
only survivors of childhood cancer [8, 9, 28, 29, 31-34], the largest cohorts being the CCSS and the 115 
BCCSS, confined to survivors diagnosed before the age of 21 and 15 years respectively [6, 9]. Eight 116 
studies included adults until the age of approximately 40 years of age [10, 22-27, 30, 35] and the 117 
remaining five studies included survivors diagnosed with cancer between 0-40 years of age [12-14, 18, 118 
36]. Five studies reported on the risks after a specific cancer diagnosis: cervical cancer [22, 27], Hodgkin 119 
lymphoma [30] or breast cancer [10, 23]. 120 
 121 
Outcomes 122 
Prematurity  123 
Fourteen studies reported the incidence of prematurity (gestational age less than 37 weeks) [8-13, 22-124 
27, 30, 31] For this outcome, in total 17,495 cancer survivors were compared to 6,070,504 controls. The 125 
relative risk in the random effects model of a preterm delivery for cancer survivors was 1.56 (95% CI 126 
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1.37 – 1.77), with moderate to high heterogeneity (I2 = 82%, p <0.01) (Figure 2A). The funnel plot did not 127 
suggest publication bias (supplementary Figure, online only). Prematurity in high risk groups, e.g. after 128 
radiotherapy or (if available) after abdominal radiotherapy, was reported in eight of these studies. The 129 
random effects meta-analysis of the four studies which also provided incidence data showed a relative 130 
risk of 2.27 (95% CI 1.34 – 3.82) (Figure 6A) [9, 30, 31, 36]. Four studies only reported ratios but not 131 
exact number, of which two showed similar effect sizes [8, 35], one did not find an increased risk [13] 132 
and one found an increased risk in those treated with radiotherapy only, but not in survivors treated 133 
with radiotherapy in combination with chemotherapy [25] (Appendix C, online only). 134 
 135 
Low birth weight 136 
Twelve studies of those reporting on prematurity also reported the incidence of low birth weight 137 
(<2.500g), comparing in total 19,073 cancer survivors to 6,099,456 controls [8-13, 22, 24-27, 31]. Meta-138 
analysis showed a significantly higher risk of having a baby with a low birth weight in cancer survivors 139 
when compared to controls (RR 1.47 (95% CI 1.24 – 1.73). Due to the high heterogeneity (I2 = 82%, p 140 
<0.01), the random effects model was employed (Figure 2B). The funnel plot did not reveal publication 141 
bias (supplementary Figure, online only). Low birth weight after high-risk treatment was reported in 6 142 
studies [8, 9, 13, 25, 31, 35], but only 2 studies reported incidence numbers which prohibited meta-143 
analysis (Appendix C, online only). RR ranged from 1.38 (95% CI 1.03 – 1.85) after any radiotherapy 144 
versus controls [8] to 2.31 (95% CI 1.50 – 3.55) after abdominal radiotherapy in comparison to survivors 145 
not treated with radiotherapy [9] (Appendix C, online only).  146 
 147 
Small for gestational age  148 
Six studies (comparing in total 12,236 cancer survivors to 5,887,753 controls) reported on the outcome 149 
of small for gestational age, defined as a weight less than the 10th percentile for that gestational age in 150 
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the reference population [8, 10-12, 31, 36]. The risk of having a small for gestational age baby was not 151 
statistically significant different for cancer survivors compared to controls (RR 0.99 (95% CI 0.81 – 1.22) 152 
in the random effects model. There was high heterogeneity amongst the studies (I2 = 89%, p <0.01) 153 
(Figure 2C). The funnel plot did not reveal any significant publication bias (supplementary Figure, online 154 
only). Two studies reported on the risk on small for gestational age after radiotherapy: one did not 155 
detect any increased risk after radiotherapy alone or in combination with chemotherapy [35] and the 156 
other found an increased odds ratio (4.0, 95% CI 1.6 – 9.8) after a radiation dose of >500cGy to the 157 
uterus, but no significant effect at lower doses [31] (Appendix C, online only). 158 
 159 
Spontaneous vaginal delivery 160 
There were five studies that reported on the incidence of spontaneous vaginal deliveries, in total 161 
reporting on 3,497 cancer survivors and 24,370 controls [12, 13, 23, 24, 28]. In the random effect model, 162 
cancer survivors were equally likely to have a spontaneous vaginal delivery: relative risk was 0.95 (95% 163 
CI 0.84 – 1.07) (Figure 3A). Heterogeneity was high (I2 = 82%, p <0.01) and the funnel plot showed a 164 
deviation, a study of breast cancer survivors, which showed that breast cancer survivors were more 165 
likely to have a spontaneous vaginal delivery (supplementary Figure, online only) [23].  166 
 167 
Assisted vaginal delivery 168 
Six studies reported the incidence of assisted vaginal deliveries, in 10,710 survivors and 1,771,131 169 
controls [12-14, 23, 27, 28]. The relative risk of an assisted vaginal delivery was 1.10 (95% CI 1.02 – 1.18) 170 
(Figure 3B). Heterogeneity was low to moderate (I2 = 49%, p = 0.08) and the funnel plot showed a 171 
deviation with overrepresentation of studies on the left side of the plot, presenting small studies not 172 
showing a significant increase in the risk (supplementary Figure, online only). The risk of assisted vaginal 173 
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delivery after abdominal radiation was only assessed in one sub study with 6 survivors [28], and one 174 
study reported no increased risk after treatment with (any) radiotherapy [13] (Appendix C, online only). 175 
 176 
Emergency caesarean section 177 
Five studies with in total 5,471 survivors and 45,593 controls reported the incidence of emergency 178 
caesarean sections in their cohorts [9, 12, 13, 27, 28]. The relative risk was 1.22 (95% CI 1.15 – 1.30) 179 
(Figure 3C). There was no heterogeneity (I2 = 0%, p = 0.46) and the funnel plot did not suggest 180 
publication bias (supplementary Figure, online only). The two studies that reported on the risk on an 181 
emergency caesarean section after radiotherapy [13] or abdominal radiotherapy [9] showed no 182 
increased risk (Appendix C, online only). 183 
 184 
Elective caesarean section 185 
An elective caesarean section occurred more often in cancer survivors than in controls. Five studies 186 
reported on 6,786 survivors and 42,089 controls [8, 9, 12, 13, 27]. The relative risk of elective caesarean 187 
section was 1.38 (95% CI 1.13 – 1.70). Heterogeneity was high (I2 = 86%, p <0.01), therefore the random 188 
effects model was employed (Figure 3D). The funnel plot suggested no significant publication bias 189 
(supplementary Figure, online only). The risk in survivors treated with radiotherapy to the abdomen was 190 
only reported in the BCCSS cohort, showing an increased risk of 1.46 (1.07 – 1.99). The risk from any 191 
radiotherapy was reported to be not elevated in two other studies [8, 13] (Appendix C, online only). 192 
 193 
Antepartum haemorrhage 194 
Three studies reported the incidence of antepartum haemorrhage [12, 14, 25]. The definition of 195 
antepartum haemorrhage varied between the studies. Hagger et al defined it as occurrence of placental 196 
abruption, placenta previa, or other excessive bleeding during labor and delivery [25]. In contrast, Rad et 197 
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al[14] and Van der Kooi et al[12] based their outcome on ICD 10, where ‘antepartum haemorrhage’ does 198 
not include placenta praevia or abruptio placentae, as those outcomes were separately reported.  199 
For this outcome, in total 10,505 cancer survivors were compared to 1,759,869 controls. The 200 
relative risk of antepartum haemorrhage for cancer survivors was not significant with an RR of 1.06 (95% 201 
CI 0.88 – 1.29), while there was no heterogeneity of this RR (I2 = 0%, p = 0.86) (Figure 4A). The funnel 202 
plot did not suggest publication bias (supplementary Figure, online only). None of the studies reported 203 
on the risk in a high-risk survivor population, e.g., after abdominal radiotherapy. 204 
 205 
Postpartum haemorrhage 206 
Postpartum haemorrhage was reported in six studies [9, 12-14, 25, 28]. Three studies [9, 12, 14] based 207 
postpartum haemorrhage on O72 of ICD 10 which defines postpartum haemorrhage as blood loss >500 208 
mL after vaginal delivery or >1000 mL after caesarean delivery. In contrast, Melin et al [13] and Lie Fong 209 
et al [28] defined postpartum haemorrhage as >1000 mL while Hagger et al [25] defined it as >500 mL.    210 
The incidence of postpartum haemorrhage was compared between in total 14,314 cancer 211 
survivors and 1,795,524 controls. Cancer survivors were at increased risk of postpartum haemorrhage 212 
(RR: 1.18; 95% CI 1.02 – 1.36) (Figure 4B). Heterogeneity across studies was substantial (I2 = 77%, p 213 
<0.01), therefore the random effects model is presented; the funnel plot did not suggest publication bias 214 
(supplementary Figure, online only). Adjustment for parity and maternal age had reduced the effect 215 
sizes in some of the original papers [9, 13]. Postpartum haemorrhage after (abdominal) radiotherapy 216 
was reported in three studies, in one it is described not to have an increased risk but without numerical 217 
data [13], therefore a meta-analysis was not feasible. One small study found an increased risk in the 218 
subgroup of 6 abdominally radiated survivors [28], and one analysis from the BCCSS found no increased 219 
risk after adjustment for confounding (RR 1.33 (95% CI 0.84 – 1.07) compared to survivors not treated 220 
with any radiotherapy [9] (Appendix C, online only). 221 
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 222 
Congenital abnormalities 223 
Twelve studies reported the prevalence of congenital abnormalities in a total cohort of 23,099 cancer 224 
survivors and 254,264 controls [8, 12, 18, 24-26, 28-30, 32-34]. The definition of congenital 225 
abnormalities ranged from ‘coded as ICD diagnoses (ICD8 740-760)’ to ‘presence of any malformation’. 226 
All reported anomalies are pooled in this meta-analysis. The resulting pooled relative risk of congenital 227 
abnormalities appears to be higher in the cancer survivor group, with an RR of 1.10 (95% CI 1.02 – 2.20) 228 
(Figure 5). 95% CI There was moderate observed heterogeneity (I2 = 45%, p = 0.05) and the funnel plot 229 
did not suggest publication bias (supplementary Figure, online only). Five studies also reported 230 
incidence numbers of congenital abnormalities after high-risk radiation [18, 28-30, 32, 33]. The fixed 231 
effects model showed a non-significant RR of 1.15 (95% CI 0.76 – 1.75) in keeping with the statistically 232 
non-significant reported risks or odds ratios in all the source articles (Appendix C, online only).  233 
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Discussion 234 
Principal findings 235 
This systematic review and meta-analysis summarizes the evidence for risks in perinatal outcomes in 236 
female cancer survivors. Outcome measures investigated were low birth weight, preterm birth, small for 237 
gestational age, mode of delivery, antepartum haemorrhage, postpartum haemorrhage, and congenital 238 
abnormalities. Offspring of cancer survivors are at increased risk of prematurity and a low birth weight, 239 
but do not face an increased risk of being small for gestational age. Cancer survivors are at increased risk 240 
of elective and emergency caesarean section as well as assisted vaginal delivery, and postpartum but 241 
not antepartum haemorrhage. 242 
Cancer treatment protocols can include chemotherapy and radiotherapy. Irradiation of the abdomen 243 
can damage the uterine vasculature and the muscular development of the uterus [39]. Endometrial 244 
function, possibly partly due to impaired blood supply, has also been postulated to be defective. 245 
Impairment of decidualization could interfere with normal placentation and trophoblast invasion. In 246 
addition, impairment of uterine vasculature leading to impaired fetal-placental blood flow may cause 247 
fetal growth restriction, and reduced uterine elasticity and volume could lead to preterm delivery or 248 
postpartum haemorrhage [39, 40]. Smaller uterine volumes can also be the result of hormonal 249 
deficiency as a consequence of ovarian failure [40].  250 
Although the risks of a premature birth and low birth weight were increased, the pooled estimates 251 
showed no evidence for increased risks  of offspring being small for gestational age. Despite this 252 
reassurance, future research on very premature deliveries, such as before 32 weeks of gestation instead 253 
of the 37 weeks of gestation that is now most often evaluated, may be of value. Very premature birth 254 
may be of a greater consequence for future health and well-being [41], even if the offspring is not small 255 
for gestational age. One study reported the risk of small for gestational age to be increased only after a 256 
high radiation dose [31]. The effect of radiation dose to the uterus has not been sufficiently examined to 257 
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review, but it is likely that a distinction between higher and lower dosages of radiotherapy will reveal an 258 
increased risk currently obscured by pooling all dosages.  259 
There was a markedly increased risk (40%) in elective caesarean section, although one study showed 260 
that this risk may have reduced in more recent years [12]. There was also an increased risk of an 261 
emergency caesarean section (by 22%), and the need for assistance during a vaginal delivery (by 10%). 262 
These increased risks may be the reflection of an increased awareness and pro-active management of 263 
women treated for cancer, specifically following treatment with abdominal radiotherapy. This analysis 264 
showed an increased risk of postpartum haemorrhage, indicating that a proactive approach to 265 
prevention may be warranted. 266 
The meta-analysis indicates an increased risk of congenital abnormality. Congenital abnormalities could 267 
be a result of germ cell mutagenicity cause by chemotherapy or irradiation of the ovarian follicle pool. 268 
Most evidence on radiation and chemical induced mutations is based on germ cells of mice [42]. In 269 
humans however, long-term follow-up studies of the offspring of Japanese atomic bomb survivors did 270 
not indicate an increased risk of congenital abnormalities as a result of parental radiation exposure [43, 271 
44]. The apparent increased risk of congenital abnormalities is likely to be an example of Simpson’s 272 
paradox, a statistical phenomenon in which certain effects observed in different groups or cohorts 273 
disappear or reverse when the groups are combined. In such cases there is often an unidentified 274 
confounding variable introduced either by the recruitment of subjects, by the analysis for studies 275 
forming the pool, or by the analysis of pooled results [37, 38]. In the case of congenital abnormalities, 276 
the definition varies greatly – with large fluctuations in prevalence rates ranging from 1.4% [8] to 9.5% 277 
[12]. In the separate studies, only one of the twelve studies reporting on congenital abnormalities 278 
reported a higher prevalence in cancer survivors [18]. In that study, the unadjusted prevalence ratio was 279 
1.21 (95% CI 1.03 – 1.40) but after adjustment for maternal age at birth of child, parity, sex of child and 280 
birth decade of child, the adjusted prevalence ratio was 1.07 (95% CI 0.91 – 1.25). This study accounted 281 
14 
 
for 31.6% of weight in the meta-analysis. The apparent increased effect is therefore likely to be biased 282 
(or paradoxical), introduced by a heterogeneous definition of congenital abnormalities resulting in large 283 
variation in prevalence rates, and the absence of adjustment for possible confounders such as maternal 284 
age, or genetic predisposition/hereditary disease.   285 
 286 
Strengths and limitations 287 
This systematic review offers an inclusive overview of relevant publications and meta-analyses of eleven 288 
outcomes, which facilitate the interpretation of the summarized literature. A choice on relatively 289 
frequently  evaluated outcomes was made,  perinatal risks such as cardiomyopathy following treatment 290 
with anthracyclines [45], pregnancy induced hypertension [9, 46], diabetes mellitus or gravidarum [8, 9, 291 
25] and others were therefore beyond the scope of this report. The main limitation is the heterogeneity 292 
within the meta-analyses, possibly as a result of differences in types of diagnoses throughout the 293 
studies. Due to the varied designs of the observational studies and lack of individual patient data, 294 
systematic adjustment for confounders was not possible, so an over or underestimation of the relative 295 
risks could have occurred. For congenital abnormalities, this is especially striking with a possible 296 
example of the Simpson’s paradox as a result. In addition, there was no uniformity in sub-analysis of 297 
potential high-risk groups, such as women who had received radiotherapy to a field that included the 298 
uterus. Some studies reported risks after any radiotherapy, some after only radiotherapy, some after 299 
certain fields of radiotherapy. Nonetheless, these subgroups can be used as an approximation of high-300 
risk treatment groups and conclusions can be drawn where the observed risks are consistent. 301 
The increasing numbers of cancer survivors as a result of better treatment protocols, and the increasing 302 
possibilities for fertility preservation, will in the future allow more survivors to consider a pregnancy. In 303 
the near future, more survivors who otherwise would not have had the possibility of reproduction, who 304 
are likely to have been exposed to higher doses of chemotherapy and radiotherapy than those whose 305 
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fertility was not impaired, may become pregnant as a result of improving fertility preservation 306 
techniques such as vitrification of oocytes and ovarian tissue cryopreservation [47-49]. Possible effects 307 
of these fertility treatments have not been taken into account in these analyses, but the increase in 308 
number of pregnancies in this at-risk population underline the importance of surveillance and 309 
supervision of these pregnancies and deliveries.   310 
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Conclusions 311 
This meta-analyses confirms that survivors of cancer are at increased risk of postpartum haemorrhage, 312 
especially after abdominal radiotherapy, and of increased rates of elective and emergency caesarean 313 
section. In addition, offspring of cancer survivors are at increased risk of prematurity and a low birth 314 
weight, but not for being small for gestational age. Our results show a likely Simpson’s paradox 315 
regarding the risk of congenital abnormalities, with the true effect being no increased risk. The 316 
magnitude of the perinatal risks warrants a proactive approach from health care providers.  317 
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Figure legends: 446 
 447 
Figure 1 PRISMA flowchart showing selection of studies. 448 
Figure 2 Pooled relative risk (RR) of premature delivery (<37 weeks of gestation; A), low birth weight 449 
(<2,500 gram; B) and small for gestational age (<10th percentile; C) of cancer survivors as compared to 450 
controls.  451 
Figure 3 Pooled relative risk (RR) of mode of delivery of cancer survivors as compared to controls.  452 
Figure 4 Pooled relative risk (RR) of antepartum (A) and postpartum haemorrhage (B) of cancer survivors 453 
as compared to controls.  454 
Figure 5 Pooled relative risk (RR) of congenital abnormalities of cancer survivors as compared to 455 
controls.  456 
Figure 6 Pooled relative risk (RR) of premature delivery and congenital abnormalities after treatment 457 
with radiotherapy (A and B, respectively) of cancer survivors as compared to controls.  458 
Appendix D Funnel plots of assessed outcomes. Outer dashed lines indicate the triangular region within 459 
which 95% of studies are expected to lie in the absence of biases and heterogeneity. Vertical dotted 460 
lines depict the estimate of the random effects model and vertical dashed lines depict the estimate of 461 
the fixed effects model. RT = radiotherapy 462 
